Elder Pharmaceuticals plans to launch five products, including its top domestic brands ‘Shelcal’, in Europe this fiscal to increase the overseas revenue.

The company will be introducing these products in Europe through its subsidiaries in the UK and Bulgaria.

“In the current financial year, five products will be launched in the European countries,” the Elder Pharmaceuticals Director, Mr Alok Saxena, said in a statement today.

Among the five products to be introduced in Europe is the company’s calcium supplement for women, ‘Shelcal’, one of its largest selling pharmaceutical products in India, with annual revenues of around Rs 200 crore.

Currently, revenues from foreign markets contribute around 10 per cent to the company’s total revenue nd the management aims to take it to 20 per cent by the end of the current fiscal, Mr Saxena said.

“Our subsidiaries in the UK and Bulgaria have a strong marketing and distribution network in Europe, which will help us to increase our penetration in the market,” he said.

Elder Pharma has set a revenue target of Rs 1,000 crore for the current financial year and Rs 1,200 crore for FY’13.

The company plans to launch around 40 products in the pain management, women’s healthcare, neutraceuticals and dermatology areas in the domestic as well international markets during the next two years to achieve this target.

For the year ended March 31, 2011, the company posted net sales of Rs 959.20 crore.

Meanwhile, the shares of Elder Pharmaceuticals were trading at Rs 364.20 apiece on the Bombay Stock Exchange in the late afternoon session today, up 0.14 per cent from the previous close.

Related Topics